Skip to main content

Advertisement

Table 2 Split of drug costs into pre- and post-progression periods, per patient

From: Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma

  Pre-progression index drugs Pre-progression concomitant drugs Post-progression index drugs Post-progression subsequent melanoma drugs Post-progression concomitant drugs Pre-progression drug costs Post-progression drug costs Total drug costs
UK analysis
 NIVO + IPI (n = 177) £135,584 £4994 £17,021 £54,096 £3262 £140,578 £74,379 £214,957
 IPI (n = 167) £66,115 £1081 £4413 £145,037 £4032 £67,196 £153,482 £220,678
 NIVO (n = 170) £109,653 £1621 £25,936 £99,448 £2843 £111,274 £128,266 £239,540
 Difference (NIVO + IPI vs. IPI 105% 362% 286% − 63% − 19% 109% − 52% − 3%
 Difference (NIVO + IPI vs. NIVO) 24% 208% − 34% − 46% 15% 26% − 42% − 10%
Germany analysis
 NIVO + IPI (n = 177) €133,743 €10,621 €17,106 €52,940 €8897 €144,364 €78,943 €223,307
 IPI (n = 167) €63,773 €2646 €4250 €152,395 €9865 €66,419 €166,510 €232,929
 NIVO (n = 170) €110,977 €5901 €26,235 €97,889 €7749 €116,878 €131,873 €248,751
 Difference (NIVO + IPI vs. IPI 110% 301% 302% − 65% − 10% 117% − 53% − 4%
 Difference (NIVO + IPI vs. NIVO) 21% 80% − 35% − 46% 15% 24% − 40% − 10%
  1. NIVO + IPI nivolumab + ipilimumab cohort, NIVO nivolumab monotherapy cohort, IPI ipilimumab monotherapy cohort